Amox Clav

PreclinicalSmall molecule

OOtto Helve

Amox Clav is one of 2 small molecule programs targeting Gut Microbiome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gut MicrobiomeNot yet recruiting

Gut MicrobiomePreclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Gut Microbiome

#DrugCompanyPhaseTrials

L-Ornithine L-Aspartate

IInstitute of Liver and Biliary Sciences, India

Phase 3

1 2

Amox Clav

OOtto Helve

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Gut Microbiome

NCT06250413

Clinical

Trials by Indication[1]

Gut Microbiome1 trial

Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics

Not yet recruiting·OOtto Helve·N/A·NCT06250413·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amox Clav. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amox Clav compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amox Clav. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otto Helve company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOtto Helve

Amox Clav

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gut Microbiome1 trial

References

Drug Info

Quick Facts

Related News